Cerus Corp (CERS) is a publicly traded Healthcare sector company. As of May 21, 2026, CERS trades at $2.49 with a market cap of $486.90M and a P/E ratio of -33.19. CERS moved -0.19% today. Year to date, CERS is +31.22%; over the trailing twelve months it is +100.75%. Its 52-week range spans $1.12 to $3.15. Analyst consensus is strong buy with an average price target of $4.50. Rallies surfaces CERS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cerus Posts Record $233.8M 2025 Revenue, Q4 IFC Demand Jumps 50%: Chief Operating Officer Vivek Jayaraman said Cerus finished 2025 with record product revenue of $233.8 million, a 16% increase, and saw IFC demand rise over 50% in Q4 with kit sales growing to 70%. The next-generation INT200 device earned CE mark and U.S. PMA submission is on track for mid-2026.
| Metric | Value |
|---|---|
| Price | $2.49 |
| Market Cap | $486.90M |
| P/E Ratio | -33.19 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.15 |
| 52-Week Low | $1.12 |
| Volume | 11 |
| Avg Volume | 0 |
| Revenue (TTM) | $233.80M |
| Net Income | $-15.64M |
| Gross Margin | 0.00% |
3 analysts cover CERS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.50.